Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MBX

MBX Biosciences Inc

Feb 06 • 04:00PM ET

37.67

+1.62 4.49 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM IWN VXF XPH IBB VTWO SCHA IWC IHE

Index	RUT	P/E	-	EPS (ttm)	-2.39	Insider Own	41.02%	Shs Outstand	44.72M	Perf Week	2.23%
Market Cap	1.69B	Forward P/E	-	EPS next Y	-2.95	Insider Trans	3.99%	Shs Float	26.42M	Perf Month	15.73%
Enterprise Value	1.30B	PEG	-	EPS next Q	-0.63	Inst Own	70.18%	Short Float	8.74%	Perf Quarter	67.05%
Income	-80.50M	P/S	-	EPS this Y	57.10%	Inst Trans	23.50%	Short Ratio	2.90	Perf Half Y	238.45%
Sales	0.00M	P/B	4.35	EPS next Y	-18.35%	ROA	-23.59%	Short Interest	2.31M	Perf YTD	19.44%
Book/sh	8.67	P/C	4.32	EPS next 5Y	14.35%	ROE	-24.43%	52W High	44.89 -16.08%	Perf Year	234.84%
Cash/sh	8.72	P/FCF	-	EPS past 3/5Y	-53.83% -	ROIC	-20.75%	52W Low	4.81 683.67%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.68% 8.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-44.79%	Oper. Margin	-	ATR (14)	2.97	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	32.95	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.59	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	32.95	EPS Q/Q	-16.28%	SMA20	-1.63%	Beta	0.97	Target Price	61.10
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	11.19%	Rel Volume	0.43	Prev Close	36.05
Employees	43	LT Debt/Eq	0.00	Earnings	Nov 06 BMO	SMA200	95.50%	Avg Volume	795.39K	Price	37.67
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.95% -	Trades		Volume	343,790	Change	4.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$66
Dec-04-25	Initiated	Goldman	Sell	$18
Nov-04-25	Initiated	TD Cowen	Buy
Oct-15-25	Initiated	Truist	Buy	$50
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Show Previous Ratings

Jan-22-26 08:00AM	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair (GlobeNewswire)
Jan-11-26 04:00PM	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 11:11PM	MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation (Insider Monkey)
08:00AM	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% (Zacks)
09:20AM	Loading…
09:20AM	Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus (Zacks)
Nov-18-25 08:00AM	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-14-25 09:55AM	Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Nov-06-25 08:00AM	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +9.71%
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet (Zacks) +8.69%
Oct-20-25 08:00AM	MBX Biosciences to Participate in November Investor Conferences (GlobeNewswire) +7.64%
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) -5.99%
Oct-09-25 09:55AM	Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Oct-08-25 07:00AM	Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates (Newsfile)
08:00AM	Loading…
Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:37AM	Loading…
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CORNELIUS JAMES M	Former Director	Jan 12 '26	Proposed Sale	35.74	30,864	1,102,991		Jan 12 03:41 PM
Hawryluk P. Kent	President & CEO	Oct 24 '25	Option Exercise	3.25	182,859	594,292	664,256	Oct 28 08:03 AM
Hawryluk P. Kent	President & CEO	Oct 20 '25	Buy	13.64	20,000	272,790	468,277	Oct 21 05:43 PM
Hoerter Steven L.	Director	Oct 17 '25	Buy	13.25	20,000	264,984	20,000	Oct 20 04:44 PM
Heron Patrick J	Director	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30 04:59 PM
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10 08:39 AM
GORDON CARL L	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:56 PM
GORDON CARL L	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:56 PM
ORBIMED ADVISORS LLC	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:52 PM
ORBIMED ADVISORS LLC	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:52 PM

Open in Screener

KRRO

Korro Bio Inc

Feb 06 • 04:00PM ET

12.57

+1.03 8.93 %

Healthcare • Biotechnology • USA • NASD

Peers: BEAM EDIT NTLA CRSP RGNX FDMT VYGR ARVN SGMO CRBU

| Held by: VTI IWM LFSC IWN VXF VTWO IWC ITOT VHT IWV

Index	RUT	P/E	-	EPS (ttm)	-9.42	Insider Own	45.35%	Shs Outstand	9.40M	Perf Week	-5.70%
Market Cap	118.38M	Forward P/E	-	EPS next Y	-8.10	Insider Trans	0.00%	Shs Float	5.11M	Perf Month	48.06%
Enterprise Value	69.57M	PEG	-	EPS next Q	-2.07	Inst Own	71.36%	Short Float	21.35%	Perf Quarter	-61.14%
Income	-88.42M	P/S	16.06	EPS this Y	3.63%	Inst Trans	18.36%	Short Ratio	2.00	Perf Half Y	-20.74%
Sales	7.37M	P/B	1.19	EPS next Y	10.33%	ROA	-43.65%	Short Interest	1.09M	Perf YTD	56.93%
Book/sh	10.54	P/C	1.27	EPS next 5Y	5.84%	ROE	-63.46%	52W High	55.89 -77.51%	Perf Year	-67.84%
Cash/sh	9.93	P/FCF	-	EPS past 3/5Y	57.64% 21.83%	ROIC	-62.91%	52W Low	5.20 141.53%	Perf 3Y	-93.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-45.55% -39.89%	Gross Margin	33.82%	Volatility	9.21% 9.50%	Perf 5Y	-99.44%
Dividend TTM	-	EV/Sales	9.44	EPS Y/Y TTM	21.61%	Oper. Margin	-1282.04%	ATR (14)	1.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.71	Sales Y/Y TTM	-	Profit Margin	-1199.53%	RSI (14)	62.44	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.71	EPS Q/Q	14.80%	SMA20	16.81%	Beta	2.99	Target Price	22.38
Payout	-	Debt/Eq	0.45	Sales Q/Q	-	SMA50	42.76%	Rel Volume	0.32	Prev Close	11.54
Employees	104	LT Debt/Eq	0.42	Earnings	Nov 12 AMC	SMA200	-34.75%	Avg Volume	545.38K	Price	12.57
IPO	Oct 03, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.98% 67.56%	Trades		Volume	173,947	Change	8.93%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-26	Upgrade	Piper Sandler	Neutral → Overweight	$30
Jan-29-26	Upgrade	H.C. Wainwright	Neutral → Buy	$20
Jan-29-26	Upgrade	Chardan Capital Markets	Neutral → Buy	$15
Jan-28-26	Upgrade	Oppenheimer	Perform → Outperform	$22
Jan-28-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$21
Nov-13-25	Downgrade	William Blair	Outperform → Mkt Perform
Nov-13-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$8
Nov-13-25	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-13-25	Downgrade	Piper Sandler	Overweight → Neutral	$11
Nov-13-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-25	Downgrade	Chardan Capital Markets	Buy → Neutral	$7
Nov-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$74
Apr-16-25	Initiated	Chardan Capital Markets	Buy	$25
Jan-10-25	Initiated	Oppenheimer	Outperform	$155
Oct-21-24	Initiated	Raymond James	Strong Buy	$153
Aug-14-24	Initiated	William Blair	Outperform	$180
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100

Show Previous Ratings

Feb-02-26 09:53AM	H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO) (Insider Monkey)
Jan-30-26 07:35AM	Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? (Zacks)
03:08AM	Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE (MarketBeat)
Jan-29-26 09:35AM	First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls (The Fly) +13.86%
Jan-20-26 08:00AM	Korro to Host Virtual Analyst Day on January 27, 2026 (GlobeNewswire)
08:00AM	Loading…
Jan-08-26 08:00AM	Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.77%
Nov-13-25 09:37AM	Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing (Investor's Business Daily) -79.31%
09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
Nov-12-25 05:59PM	This biotech is halting its work with Novo Nordisk and laying off more people (MarketWatch)
05:40PM	Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs (GlobeNewswire)
Sep-02-25 04:30PM	Korro to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire) +17.25%
Aug-12-25 07:00AM	Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.25%
Jul-21-25 08:00AM	Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 (GlobeNewswire)
May-14-25 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.26%
10:31AM	Loading…
May-09-25 10:31AM	Korro Bio price target lowered to $53 from $130 at H.C. Wainwright (TipRanks)
May-07-25 04:30PM	Korro Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.85% +10.55%
Apr-01-25 07:30AM	Korro Appoints Biotech Industry Veteran, Loic Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire) -8.39%
07:30AM	Korro Appoints Biotech Industry Veteran, Lo c Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-28-25 06:18PM	Korro Bio: Promising Early Stage RNA Editing Company (Seeking Alpha) -5.11%
Mar-18-25 07:00AM	Korro Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-25 07:26AM	FDA grants orphan drug status for Korro Bio's AATD therapy (Pharmaceutical Business Review)
Mar-14-25 08:00AM	KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Feb-26-25 08:00AM	Korro to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-13-25 08:00AM	Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update (GlobeNewswire) +8.20%
Jan-07-25 08:00AM	Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.23%
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire)
Nov-21-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.70%
07:30AM	Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Nov-14-24 08:00AM	Korro to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.65%
04:05PM	Loading…
Nov-12-24 04:05PM	Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -11.37% -15.55%
Nov-04-24 07:25AM	Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board (GlobeNewswire)
Oct-21-24 04:15PM	Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. (Investor's Business Daily) -5.22% -7.70%
Oct-16-24 04:20PM	Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed. (Investor's Business Daily) +93.66%
Sep-30-24 08:00AM	Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Open in Screener

NET

Cloudflare Inc

Feb 06 • 04:00PM ET

173.21

+10.16 6.23 %

Technology • Software - Infrastructure • USA • NYSE

Peers: AMZN MSFT GOOGL ZS CSCO CRWD AKAM OKTA VZ FSLY

| Held by: VTI VO VUG VXF VOT VGT CIBR IWP CGGR IWF

Index	-	P/E	-	EPS (ttm)	-0.30	Insider Own	10.85%	Shs Outstand	315.17M	Perf Week	-2.33%
Market Cap	60.67B	Forward P/E	146.60	EPS next Y	1.18	Insider Trans	-4.28%	Shs Float	312.28M	Perf Month	-14.59%
Enterprise Value	60.13B	PEG	5.44	EPS next Q	0.27	Inst Own	79.62%	Short Float	3.21%	Perf Quarter	-24.20%
Income	-103.04M	P/S	30.13	EPS this Y	21.82%	Inst Trans	0.27%	Short Ratio	3.03	Perf Half Y	-17.69%
Sales	2.01B	P/B	45.03	EPS next Y	29.32%	ROA	-2.33%	Short Interest	10.01M	Perf YTD	-12.14%
Book/sh	3.85	P/C	14.99	EPS next 5Y	26.97%	ROE	-8.88%	52W High	260.00 -33.38%	Perf Year	20.04%
Cash/sh	11.56	P/FCF	293.50	EPS past 3/5Y	34.82% 8.13%	ROIC	-2.95%	52W Low	89.42 93.70%	Perf 3Y	212.03%
Dividend Est.	-	EV/EBITDA	809.45	Sales past 3/5Y	36.50% 42.21%	Gross Margin	75.19%	Volatility	8.00% 5.84%	Perf 5Y	115.22%
Dividend TTM	-	EV/Sales	29.86	EPS Y/Y TTM	-7.44%	Oper. Margin	-9.35%	ATR (14)	11.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.04	Sales Y/Y TTM	28.06%	Profit Margin	-5.12%	RSI (14)	43.91	Recom	2.05
Dividend Gr. 3/5Y	- -	Current Ratio	2.04	EPS Q/Q	91.74%	SMA20	-3.84%	Beta	2.00	Target Price	232.45
Payout	-	Debt/Eq	2.60	Sales Q/Q	30.68%	SMA50	-9.85%	Rel Volume	1.63	Prev Close	163.05
Employees	4263	LT Debt/Eq	1.59	Earnings	Feb 10 AMC	SMA200	-10.22%	Avg Volume	3.30M	Price	173.21
IPO	Sep 13, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.34% 3.19%	Trades		Volume	5,380,535	Change	6.23%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-26	Upgrade	BTIG Research	Neutral → Buy	$199
Dec-02-25	Initiated	Barclays	Overweight	$235
Nov-10-25	Resumed	Oppenheimer	Outperform	$260
Nov-05-25	Upgrade	DZ Bank	Sell → Hold	$237
Oct-31-25	Resumed	Jefferies	Hold	$250
Jun-06-25	Initiated	KeyBanc Capital Markets	Overweight
Apr-16-25	Upgrade	Mizuho	Neutral → Outperform	$135
Mar-25-25	Upgrade	BofA Securities	Underperform → Buy	$160
Mar-20-25	Resumed	Oppenheimer	Outperform	$150
Mar-18-25	Resumed	Morgan Stanley	Overweight
Feb-11-25	Downgrade	DZ Bank	Hold → Sell	$145
Feb-07-25	Downgrade	Oppenheimer	Outperform → Perform
Feb-03-25	Downgrade	Robert W. Baird	Outperform → Neutral	$125 → $140
Jan-17-25	Upgrade	Citigroup	Neutral → Buy	$95 → $145
Jan-17-25	Initiated	Cantor Fitzgerald	Neutral	$111
Jan-03-25	Reiterated	RBC Capital Mkts	Outperform	$99 → $123
Jan-02-25	Upgrade	Goldman	Sell → Buy	$77 → $140
Dec-17-24	Upgrade	Stifel	Hold → Buy	$95 → $136
Dec-02-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-08-24	Initiated	Exane BNP Paribas	Underperform	$65

Show Previous Ratings

Feb-08-26 10:06PM	Cloudflare Earnings: What To Look For From NET (StockStory)
Feb-07-26 07:30AM	Software stocks have been crushed. Here's how to play the sector as the dust settles. (MarketWatch)
Feb-06-26 02:48PM	Take-Two, Mondelez Get Analyst Attention (Barrons.com) +6.23%
12:32PM	Cloudflare Q4 earnings set to show continued AI-driven growth: analysts (Proactive)
12:00PM	Cybersecurity Stock Gearing Up For Massive Week (Schaeffer's Research)
10:45AM	Loading…
10:45AM	Cisco Stock Holds Strong Amid Tech Selling As Earnings Come Into Focus (Investor's Business Daily)
10:18AM	Cloudflare to Post Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-05-26 05:15PM	Reddit Inc. (RDDT) Tops Q4 Earnings and Revenue Estimates (Zacks)
08:53AM	Software ate the world. Now, Wall Street is worried AI will eat software. (MarketWatch)
Feb-04-26 12:42PM	The Social Security data breach is a national-security disaster that could hurt Americans for the rest of their lives: whistleblower (MarketWatch)
10:00AM	Analysts Estimate Porch Group, Inc. (PRCH) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:16AM	Cloudflares long-term growth opportunity is underappreciated, says BTIG (Investing.com)
08:37AM	Broadcom Is 'Uncle Sam Of AI,' Says Futurum Equities As It Lists 15 Non-Mag7 AI Disruptors (Benzinga)
08:00AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More (24/7 Wall St.)
Feb-03-26 05:50PM	Cloudflare (NET) Dips More Than Broader Market: What You Should Know (Zacks) -6.64%
05:25PM	Loading…
05:25PM	Intapp (INTA) Q2 Earnings and Revenues Beat Estimates (Zacks)
02:51PM	Why Cloudflare (NET) Shares Are Getting Obliterated Today (StockStory)
10:38AM	Microchip to Report Q3 Earnings: What's in Store for the Stock? (Zacks)
10:00AM	Cloudflare (NET) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-02-26 04:01PM	ChatGPT Thinks Cloudflare Stock Will Close At This Price In The Next 60 Days (Benzinga)
08:38AM	4 Software Stocks Set to Pull Off a Beat This Earnings Season (Zacks)
Feb-01-26 02:38AM	Morgan Stanley Maintains a Buy on Cloudflare (NET) (Insider Monkey)
Jan-30-26 09:15AM	Kimball Electronics Gears Up to Report Q2 Earnings: What to Expect? (Zacks)
09:00AM	Is Trending Stock Cloudflare, Inc. (NET) a Buy Now? (Zacks)
Jan-29-26 11:34PM	1 of Wall Street's Favorite Stock to Own for Decades and 2 Facing Challenges (StockStory)
Jan-28-26 05:50PM	Cloudflare (NET) Declines More Than Market: Some Information for Investors (Zacks) -10.23%
03:00PM	Why Cloudflare (NET) Stock Is Down Today (StockStory)
03:00PM	Quantum's Next Winners? 3 Enablers With 10%+ Projected Growth in 2026 (Zacks)
01:23PM	CoreWeave Stock Earns RS Rating Upgrade (Investor's Business Daily)
08:55AM	Should You Chase the Clawdbot Rally in Cloudflare Stock? (Barchart)
05:24PM	Loading…
Jan-27-26 05:24PM	Cloudflare's stock pops on viral Moltbot. Here's how a cybersecurity company became the newest AI winner. (MarketWatch) +8.77%
02:02PM	The Viral AI Bot That Sent Cloudflare Stock to the Moon (Barrons.com)
12:55PM	S&P 500 Hits New Records, GM Stock Jumps 8% On Earnings: What's Moving Markets Tuesday? (Benzinga)
11:41AM	Why Are Cloudflare (NET) Shares Soaring Today (StockStory)
10:40AM	Cloudflare Stock Pops On Anthropic's Claude AI Tools. Zoom Also Gets Anthropic Boost. (Investor's Business Daily)
09:22AM	Cloudflare surges as viral AI agent buzz lifts expectations (Reuters)
09:04AM	The Viral AI Bot That Has Sent Cloudflare Stock to the Moon (Barrons.com)
08:44AM	Cloudflare Stock Keeps On Surging. A Viral AI Bot Has Investors Excited. (Barrons.com)
07:45AM	DigitalOcean stock jumps as Clawdbot AI agent fuels investor optimism (Investing.com)
07:31AM	Cloudflare (NET) Moves 9.2% Higher: Will This Strength Last? (Zacks)
06:57AM	Cloudflare shares continue higher as Clawdbot excitement builds (Investing.com)
05:40AM	Healthcare stocks slide, and other early market movers (MarketWatch)
05:13AM	Stock Market Today: Dow Futures Slip, S&P 500 Gains Amid Trump's Fresh Tariffs On South Korea- General Motors, UnitedHealth, Cloudflare In Focus (Benzinga)
Jan-26-26 03:13PM	Why Cloudflare is surging: Clawdbot AI agents and the future of edge computing (Investing.com) +9.17%
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
01:12PM	Stock Market Today: Trump's Medicare announcement slams health insurers (TheStreet)
12:10PM	Cloudflare (NET) Shares Skyrocket, What You Need To Know (StockStory)
11:01AM	What's Going On With Cloudflare Stock Today? (Benzinga)
Jan-25-26 11:33PM	2 Growth Stocks to Stash and 1 We Question (StockStory)
03:59AM	Investors Watch Cloudflare's (NET) Network and Edge AI Capabilities After Market Outperform Call (Insider Monkey)
Jan-23-26 04:00PM	Baillie Gifford's Strategic Moves: Cloudflare Inc. Reduction by 23% (GuruFocus.com) +9.17%
12:33PM	Cloudflare (NET) Acquires The Astro Technology Company (Insider Monkey)
10:04AM	'Jobs, jobs, jobs' the AI mantra in Davos as fears take back seat (Reuters)
08:55AM	How to Boost Your Portfolio with Top Computer and Technology Stocks Set to Beat Earnings (Zacks)
07:39AM	Here's Why Wall Street is Bullish on ?Cloudflare, Inc. (NET) (Insider Monkey)
Jan-22-26 08:55AM	How to Boost Your Portfolio with Top Computer and Technology Stocks Set to Beat Earnings (Zacks)
Jan-21-26 06:00PM	Cloudflare (NET) Stock Declines While Market Improves: Some Information for Investors (Zacks)
08:40AM	Cloudflare price target lowered to $225 from $275 at Truist (TipRanks)
Jan-20-26 01:30PM	Why Cloudflare (NET) Stock Options Could Be Due for a Comeback Trade (Barchart)
06:01AM	Google Has A Huge Edge Over OpenAI, Microsoft, Says Cloudflare CEO And It All Comes Down To Data: 'Whoever Has The Most...Wins' (Benzinga)
Jan-19-26 11:35PM	1 Unprofitable Stock to Target This Week and 2 We Brush Off (StockStory)
Jan-17-26 03:03AM	Google Has A Huge Edge Over OpenAI, Microsoft, Says Cloudflare CEO- And It All Comes Down To Data: 'Whoever Has The Most...Wins' (Benzinga)
Jan-16-26 01:18PM	Cloudflare Rebounds After Human Native Deal (GuruFocus.com)
09:00AM	Cloudflare Acquires Astro to Accelerate the Future of High-Performance Web Development (Business Wire)
Jan-15-26 05:50PM	Cloudflare (NET) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
04:15PM	Cloudflare Announces Date of Fourth Quarter 2025 Financial Results (Business Wire)
09:00AM	Cloudflare Strengthens Content Offering to AI Companies with Acquisition of Human Native (Business Wire)
Jan-14-26 10:57AM	Jim Cramer Highlights Cloudflare as a Buy on Weakness (Insider Monkey)
09:00AM	New Cloudflare Report Warns of a Technical Glass Ceiling Stifling AI Growth and Weakening Cybersecurity (Business Wire)
Jan-12-26 06:58AM	Despite Valuation Concerns, Cloudflare (NET) Still Offers Strong Upside (Insider Monkey)
Jan-11-26 01:59PM	RBC and Stifel Stay Bullish on Cloudfare (NET) (Insider Monkey)
Jan-09-26 05:50PM	Cloudflare (NET) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
09:01AM	ChatGPT Thinks Cloudflare Stock Will Close At This Price In The Next 60 Days (Benzinga)
Jan-08-26 11:40AM	Cloudflare (NET) Stock Trades Down, Here Is Why (StockStory) -7.82%
Jan-07-26 06:00PM	Cloudflare (NET) Ascends While Market Falls: Some Facts to Note (Zacks)
08:55AM	How to Find Strong Computer and Technology Stocks Slated for Positive Earnings Surprises (Zacks)
07:46AM	Cybersecurity Stocks: More Acquisitions Expected In 2026 Amid AI Boom (Investor's Business Daily)
Jan-06-26 12:10PM	Will Cloudflare (NET) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:00AM	Cloudflare, Inc. (NET) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jan-02-26 07:00AM	AI Cybersecurity Stocks in 2025 and What's Next for the Sector (Newsfile)
Dec-31-25 05:50PM	Why Cloudflare (NET) Dipped More Than Broader Market Today (Zacks)
11:42AM	Cloudflare, Inc (NET) Up 79.8% YTD, Wall Street Remains Bullish (Insider Monkey)
Dec-29-25 11:48AM	Cybersecurity: The innovation and worries around agentic AI (Yahoo Finance Video)
Dec-28-25 10:00AM	Cyber scams on the rise: How to avoid getting phished by hackers (Yahoo Finance Video)
Dec-27-25 10:00AM	Phishing scams becoming prevalent on LinkedIn: How to spot them (Yahoo Finance Video)
02:20AM	Stifel: Cloudflare (NET) a Key Player in Emerging AI Security Market (Insider Monkey)
Dec-26-25 10:12AM	Cloudflare vs. Fastly: Which CDN Player is a Safe Investment Bet? (Zacks)
Dec-23-25 11:04PM	3 Reasons NET Has Explosive Upside Potential (StockStory)
10:01AM	Can Cloudflare's Edge AI Inference Reshape Cost Economics? (Zacks)
07:16AM	AI-Driven Cybersecurity Boom Makes These 4 Stocks Worth Buying (Zacks)
Dec-22-25 03:01PM	Why Cloudflare (NET) Stock Is Up Today (StockStory)
09:00AM	Investors Heavily Search Cloudflare, Inc. (NET): Here is What You Need to Know (Zacks)
Dec-21-25 09:45AM	Cloudflare (NET) Partners with JD.com to Create an International Platform (Insider Monkey)
Dec-19-25 09:00AM	Cloudflare Publishes Fifth Annual Impact Report (Business Wire)
08:10AM	The Zacks Analyst Blog Amazon, Atlassian and Cloudflare (Zacks)
Dec-18-25 05:50PM	Cloudflare (NET) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
09:53AM	3 Cloud Computing Stocks That Investors Can Opt to Buy Before 2026 (Zacks)
Dec-17-25 02:24PM	Why Cloudflare is AWS for the AI Era and So Much More (24/7 Wall St.)
11:05AM	Can Datadog's Strong Enterprise Base Drive the Next Growth Phase? (Zacks)
09:55AM	Wall Street Analysts See a 26.38% Upside in Cloudflare (NET): Can the Stock Really Move This High? (Zacks)

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hawkins Mark J	Director	Feb 02 '26	Sale	176.19	134	23,609	10,588	Feb 03 04:22 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Feb 02 '26	Sale	176.19	3,000	528,570	101,101	Feb 03 04:20 PM
DOUGLAS KRAMER	Officer	Feb 02 '26	Proposed Sale	176.19	3,000	528,570		Feb 02 04:04 PM
MARK HAWKINS	Director	Feb 02 '26	Proposed Sale	176.19	134	23,609		Feb 02 04:02 PM
Ledbetter Carl	Director	Jan 27 '26	Sale	211.16	15,000	3,167,414	953,073	Jan 28 04:29 PM
Ledbetter Carl	Officer	Jan 27 '26	Proposed Sale	211.16	60,000	12,669,660		Jan 27 04:03 PM
SEIFERT THOMAS J	Chief Financial Officer	Jan 20 '26	Sale	178.37	10,000	1,783,682	137,486	Jan 21 05:13 PM
THOMAS SEIFERT	Officer	Jan 20 '26	Proposed Sale	184.17	10,000	1,841,700		Jan 20 04:34 PM
Zatlyn Michelle	President and Board Co-Chair	Jan 15 '26	Sale	190.05	25,641	4,873,012	24,555	Jan 15 08:19 PM
Zatlyn Michelle	President and Board Co-Chair	Jan 13 '26	Sale	187.96	25,641	4,819,399	24,555	Jan 15 08:19 PM
Zatlyn Michelle	President and Board Co-Chair	Jan 14 '26	Sale	187.67	25,641	4,811,997	24,555	Jan 15 08:19 PM
Prince Matthew	CEO & Board Co-Chair	Jan 07 '26	Sale	201.84	52,384	10,573,426	0	Jan 08 07:31 PM
Prince Matthew	CEO & Board Co-Chair	Jan 06 '26	Sale	194.77	52,384	10,202,623	0	Jan 08 07:31 PM
Prince Matthew	CEO & Board Co-Chair	Jan 08 '26	Sale	189.47	52,384	9,925,077	0	Jan 08 07:31 PM
Ledbetter Carl	Director	Jan 05 '26	Sale	198.26	6,134	1,216,136	968,073	Jan 06 04:33 PM
Graham-Cumming John	Director	Jan 05 '26	Option Exercise	44.72	2,520	112,694	497,711	Jan 06 04:31 PM
Graham-Cumming John	Director	Jan 05 '26	Sale	200.27	2,520	504,676	495,191	Jan 06 04:31 PM
Hawkins Mark J	Director	Jan 02 '26	Sale	198.90	134	26,653	10,722	Jan 06 04:30 PM
Kramer Douglas James	Chief Legal Officer	Jan 02 '26	Sale	198.54	9,000	1,786,861	104,101	Jan 06 04:23 PM
DOUGLAS KRAMER	Officer	Jan 02 '26	Proposed Sale	198.54	9,000	1,786,861		Jan 02 04:07 PM
MARK HAWKINS	Director	Jan 02 '26	Proposed Sale	198.90	134	26,653		Jan 02 04:03 PM
Ledbetter Carl	Director	Dec 29 '25	Sale	201.46	8,674	1,747,501	974,399	Dec 30 06:04 PM
Ledbetter Carl	Director	Dec 30 '25	Sale	201.25	192	38,641	974,207	Dec 30 06:04 PM
Suder Katrin	Director	Dec 22 '25	Sale	200.00	2,031	406,200	37,723	Dec 23 04:17 PM
SEIFERT THOMAS J	Chief Financial Officer	Dec 22 '25	Sale	201.69	10,000	2,016,931	137,486	Dec 23 04:14 PM
THOMAS SEIFERT	Officer	Dec 22 '25	Proposed Sale	195.68	10,000	1,956,800		Dec 22 04:25 PM
KATRIN SUSANNE SUDER	Director	Dec 22 '25	Proposed Sale	200.00	2,031	406,200		Dec 22 04:02 PM
Graham-Cumming John	Director	Dec 15 '25	Option Exercise	44.72	2,520	112,694	497,711	Dec 16 05:01 PM
Graham-Cumming John	Director	Dec 15 '25	Sale	199.37	2,520	502,425	495,191	Dec 16 05:01 PM
John Graham-Cumming	Director	Dec 15 '25	Proposed Sale	196.70	10,080	1,982,736		Dec 15 06:29 PM
Zatlyn Michelle	President and Board Co-Chair	Dec 11 '25	Sale	208.61	25,641	5,349,054	24,555	Dec 11 06:36 PM
Zatlyn Michelle	President and Board Co-Chair	Dec 10 '25	Sale	205.91	25,641	5,279,622	24,555	Dec 11 06:36 PM
Zatlyn Michelle	President and Board Co-Chair	Dec 09 '25	Sale	205.15	25,641	5,260,255	24,555	Dec 11 06:36 PM
Prince Matthew	CEO & Board Co-Chair	Dec 04 '25	Sale	203.66	52,384	10,668,765	0	Dec 05 08:02 PM
Prince Matthew	CEO & Board Co-Chair	Dec 03 '25	Sale	202.19	52,384	10,591,319	0	Dec 05 08:02 PM
Prince Matthew	CEO & Board Co-Chair	Dec 05 '25	Sale	201.23	52,384	10,541,387	0	Dec 05 08:02 PM
Matthew Prince	Officer	Dec 03 '25	Proposed Sale	204.35	471,456	96,342,034		Dec 03 05:57 PM
Hawkins Mark J	Director	Dec 01 '25	Sale	197.65	134	26,485	10,856	Dec 02 04:54 PM
Kramer Douglas James	Chief Legal Officer	Dec 01 '25	Sale	196.84	3,000	590,509	113,101	Dec 02 04:52 PM
DOUGLAS KRAMER	Officer	Dec 01 '25	Proposed Sale	196.84	3,000	590,509		Dec 01 04:07 PM
MARK HAWKINS	Director	Dec 01 '25	Proposed Sale	197.65	134	26,485		Dec 01 04:03 PM
Zatlyn Michelle	President and Board Co-Chair	Nov 20 '25	Sale	199.26	35,099	6,993,977	24,555	Nov 24 08:49 PM
Zatlyn Michelle	President and Board Co-Chair	Nov 24 '25	Sale	189.07	25,641	4,847,905	24,555	Nov 24 08:49 PM
Zatlyn Michelle	President and Board Co-Chair	Nov 21 '25	Sale	188.13	25,641	4,823,906	24,555	Nov 24 08:49 PM
SEIFERT THOMAS J	Chief Financial Officer	Nov 20 '25	Sale	194.18	41,555	8,069,178	137,486	Nov 21 06:45 PM
Michelle Zatlyn	Officer	Nov 20 '25	Proposed Sale	191.39	240,227	45,977,046		Nov 20 04:30 PM
THOMAS SEIFERT	Officer	Nov 20 '25	Proposed Sale	196.20	41,555	8,153,091		Nov 20 04:20 PM
Prince Matthew	CEO & Board Co-Chair	Nov 17 '25	Sale	204.76	52,384	10,726,358	22,175	Nov 19 07:59 PM
Prince Matthew	CEO & Board Co-Chair	Nov 18 '25	Sale	197.56	52,384	10,348,786	22,175	Nov 19 07:59 PM
Prince Matthew	CEO & Board Co-Chair	Nov 19 '25	Sale	195.32	52,384	10,231,827	22,175	Nov 19 07:59 PM
Suder Katrin	Director	Nov 19 '25	Sale	196.38	2,031	398,848	39,754	Nov 19 04:21 PM
KATRIN SUSANNE SUDER	Director	Nov 19 '25	Proposed Sale	196.38	2,031	398,848		Nov 19 04:03 PM
Riley Janel	Chief Accounting Officer	Nov 18 '25	Sale	196.51	3,488	685,418	56,144	Nov 18 05:35 PM
Ledbetter Carl	Director	Nov 17 '25	Sale	207.96	15,000	3,119,400	983,073	Nov 17 06:25 PM
Kramer Douglas James	Chief Legal Officer	Nov 03 '25	Sale	255.53	3,000	766,599	129,185	Nov 05 04:39 PM
Graham-Cumming John	Director	Nov 03 '25	Option Exercise	44.72	2,520	112,694	497,711	Nov 03 06:41 PM
Graham-Cumming John	Director	Nov 03 '25	Sale	250.83	2,520	632,096	495,191	Nov 03 06:41 PM
Hawkins Mark J	Director	Nov 03 '25	Sale	254.15	1,000	254,150	10,990	Nov 03 05:30 PM
MARK HAWKINS	Director	Nov 03 '25	Proposed Sale	254.15	1,000	254,150		Nov 03 04:07 PM
DOUGLAS KRAMER	Officer	Nov 03 '25	Proposed Sale	255.53	3,000	766,599		Nov 03 04:03 PM
Ledbetter Carl	Director	Oct 20 '25	Sale	210.65	15,000	3,159,809	998,073	Oct 20 06:54 PM
SEIFERT THOMAS J	Chief Financial Officer	Oct 20 '25	Sale	211.81	10,000	2,118,137	189,517	Oct 20 06:52 PM
THOMAS SEIFERT	Officer	Oct 20 '25	Proposed Sale	210.01	10,000	2,100,100		Oct 20 04:19 PM
Ledbetter Carl	Officer	Oct 20 '25	Proposed Sale	193.94	45,000	8,727,179		Oct 20 04:18 PM
Prince Matthew	CEO & Board Co-Chair	Oct 16 '25	Sale	220.79	107	23,625	0	Oct 16 06:45 PM
Prince Matthew	CEO & Board Co-Chair	Oct 15 '25	Sale	221.05	52,384	11,579,346	0	Oct 16 06:44 PM
Prince Matthew	CEO & Board Co-Chair	Oct 14 '25	Sale	215.51	52,384	11,289,337	0	Oct 16 06:44 PM
Prince Matthew	CEO & Board Co-Chair	Oct 16 '25	Sale	213.94	52,277	11,184,307	107	Oct 16 06:44 PM
Graham-Cumming John	Director	Oct 13 '25	Option Exercise	44.72	2,520	112,694	497,711	Oct 15 04:27 PM
Graham-Cumming John	Director	Oct 13 '25	Sale	221.36	2,520	557,829	495,191	Oct 15 04:27 PM
Zatlyn Michelle	President and Board Co-Chair	Oct 08 '25	Sale	218.45	25,641	5,601,253	14,575	Oct 09 05:50 PM
Zatlyn Michelle	President and Board Co-Chair	Oct 07 '25	Sale	218.20	25,641	5,594,911	14,575	Oct 09 05:50 PM
Zatlyn Michelle	President and Board Co-Chair	Oct 09 '25	Sale	215.38	25,641	5,522,535	14,575	Oct 09 05:50 PM
Kramer Douglas James	Chief Legal Officer	Oct 01 '25	Sale	213.48	9,000	1,921,310	132,185	Oct 01 05:19 PM
Hawkins Mark J	Director	Oct 01 '25	Sale	212.83	1,000	212,830	11,990	Oct 01 04:09 PM
DOUGLAS KRAMER	Officer	Oct 01 '25	Proposed Sale	213.48	9,000	1,921,310		Oct 01 04:02 PM
MARK HAWKINS	Director	Oct 01 '25	Proposed Sale	212.83	1,000	212,830		Oct 01 04:01 PM
Zatlyn Michelle	President and Board Co-Chair	Sep 23 '25	Sale	223.45	25,641	5,729,556	14,575	Sep 25 06:04 PM
Zatlyn Michelle	President and Board Co-Chair	Sep 24 '25	Sale	221.20	25,641	5,671,760	14,575	Sep 25 06:04 PM
Zatlyn Michelle	President and Board Co-Chair	Sep 25 '25	Sale	212.49	25,641	5,448,476	14,575	Sep 25 06:04 PM
Ledbetter Carl	Director	Sep 22 '25	Sale	223.91	15,000	3,358,639	1,013,073	Sep 22 06:32 PM
SEIFERT THOMAS J	Chief Financial Officer	Sep 22 '25	Sale	227.64	10,000	2,276,444	189,517	Sep 22 06:30 PM
THOMAS SEIFERT	Officer	Sep 22 '25	Proposed Sale	225.94	10,000	2,259,400		Sep 22 04:21 PM
Prince Matthew	CEO & Board Co-Chair	Sep 11 '25	Sale	226.46	52,384	11,863,054	0	Sep 11 06:49 PM
Prince Matthew	CEO & Board Co-Chair	Sep 10 '25	Sale	222.10	52,384	11,634,259	0	Sep 11 06:49 PM
Prince Matthew	CEO & Board Co-Chair	Sep 09 '25	Sale	217.12	52,384	11,373,601	0	Sep 11 06:49 PM
Matthew Prince	Officer	Sep 09 '25	Proposed Sale	218.56	471,456	103,041,423		Sep 09 05:02 PM
Graham-Cumming John	Director	Sep 02 '25	Option Exercise	44.72	2,530	113,142	505,406	Sep 04 05:18 PM
Graham-Cumming John	Director	Sep 02 '25	Sale	206.32	10,215	2,107,518	495,191	Sep 04 05:18 PM
Kramer Douglas James	Chief Legal Officer	Sep 02 '25	Sale	202.10	3,000	606,304	141,185	Sep 04 04:18 PM
Hawkins Mark J	Director	Sep 02 '25	Sale	201.60	1,000	201,600	12,990	Sep 04 04:14 PM
John Graham-Cumming	Director	Sep 02 '25	Proposed Sale	208.05	15,255	3,173,803		Sep 02 05:11 PM
DOUGLAS KRAMER	Officer	Sep 02 '25	Proposed Sale	202.10	3,000	606,304		Sep 02 04:05 PM
MARK HAWKINS	Director	Sep 02 '25	Proposed Sale	201.60	1,000	201,600		Sep 02 04:02 PM
Ledbetter Carl	Director	Aug 25 '25	Sale	195.73	15,000	2,935,935	1,028,073	Aug 26 05:09 PM
Zatlyn Michelle	President and Board Co-Chair	Aug 21 '25	Sale	191.71	35,100	6,729,008	14,575	Aug 25 06:21 PM
Zatlyn Michelle	President and Board Co-Chair	Aug 25 '25	Sale	195.61	25,641	5,015,699	14,575	Aug 25 06:21 PM
Zatlyn Michelle	President and Board Co-Chair	Aug 22 '25	Sale	193.23	25,641	4,954,632	14,575	Aug 25 06:21 PM
SEIFERT THOMAS J	Chief Financial Officer	Aug 20 '25	Sale	190.64	41,555	7,921,856	189,517	Aug 21 05:45 PM
Michelle Zatlyn	Officer	Aug 21 '25	Proposed Sale	192.77	240,228	46,308,752		Aug 21 04:44 PM

Open in Screener

SVRA

Savara Inc

Feb 06 • 04:00PM ET

5.30

+0.14 2.71 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE ARWR NVAX AXSM HRTX ACAD PTGX KPTI CRBP

| Held by: VTI IWM VXF XBI IWO VTWO IBB SCHA LFSC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.54	Insider Own	49.66%	Shs Outstand	172.85M	Perf Week	-1.85%
Market Cap	1.08B	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-0.02%	Shs Float	102.42M	Perf Month	-8.15%
Enterprise Value	983.82M	PEG	-	EPS next Q	-0.12	Inst Own	38.63%	Short Float	21.80%	Perf Quarter	31.51%
Income	-115.64M	P/S	-	EPS this Y	-7.26%	Inst Trans	-0.98%	Short Ratio	8.96	Perf Half Y	101.52%
Sales	0.00M	P/B	9.71	EPS next Y	14.54%	ROA	-60.91%	Short Interest	22.32M	Perf YTD	-12.11%
Book/sh	0.55	P/C	8.67	EPS next 5Y	38.07%	ROE	-78.74%	52W High	7.01 -24.34%	Perf Year	85.96%
Cash/sh	0.61	P/FCF	-	EPS past 3/5Y	-14.63% 24.35%	ROIC	-93.14%	52W Low	1.89 180.42%	Perf 3Y	112.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.20% 5.37%	Perf 5Y	244.16%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.39%	Oper. Margin	-	ATR (14)	0.33	Perf 10Y	-81.07%
Dividend Ex-Date	-	Quick Ratio	7.65	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	40.80	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.65	EPS Q/Q	-19.30%	SMA20	-7.87%	Beta	0.34	Target Price	10.81
Payout	-	Debt/Eq	0.32	Sales Q/Q	-	SMA50	-11.71%	Rel Volume	0.78	Prev Close	5.16
Employees	59	LT Debt/Eq	0.32	Earnings	Nov 12 AMC	SMA200	37.37%	Avg Volume	2.49M	Price	5.30
IPO	Oct 16, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.66% -	Trades		Volume	1,944,973	Change	2.71%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$7
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
May-29-25	Downgrade	H.C. Wainwright	Buy → Neutral	$2
Dec-20-24	Initiated	Wells Fargo	Overweight	$8
Nov-13-24	Downgrade	Evercore ISI	Outperform → In-line	$7 → $5
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

Feb-04-26 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) -5.30%
Jan-27-26 08:05AM	Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
Jan-16-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-08-26 04:05PM	PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* (Business Wire)
Dec-22-25 08:30AM	Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire) +6.94%
08:05AM	Loading…
Dec-17-25 08:05AM	Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-11-25 08:05AM	Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* (Business Wire)
Dec-02-25 08:05AM	Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow Nebulizer System (Business Wire)
Dec-01-25 01:23PM	Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences (Insider Monkey) -7.15%
Nov-20-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.35%
Nov-12-25 04:05PM	Savara Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire)
02:56AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-31-25 04:05PM	Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M (Business Wire)
Oct-30-25 11:29PM	What Does Wall Street Think About Savara Inc. (SVRA)? (Insider Monkey)
09:43PM	Loading…
Oct-29-25 09:43PM	Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants (Business Wire)
04:07PM	Savara Announces Proposed Public Offering (Business Wire)
04:01PM	Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
11:57AM	Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections (Insider Monkey)
Oct-17-25 08:05AM	Savara Announces Chief Medical Officer (CMO) Transition (Business Wire)
Oct-13-25 04:59PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-10-25 09:00AM	Savara Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SVRA (PR Newswire)
Oct-07-25 07:40AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-02-25 04:05PM	Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 (Business Wire)
Sep-29-25 02:00AM	Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-25-25 04:37PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Sep-24-25 04:25PM	Did You Lose Money on Savara Inc. (SVRA)? Levi & Korsinsky Urges Investors to Act Before November 7, 2025 (Newsfile)
Sep-23-25 10:53AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SVRA (Business Wire)
Sep-20-25 02:43AM	Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity (Insider Monkey)
Sep-11-25 04:18PM	Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025 (Newsfile) -6.27%
09:00AM	Loading…
Sep-02-25 09:00AM	Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis (Business Wire)
Aug-26-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.41%
Aug-23-25 04:16AM	Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough (Insider Monkey)
Aug-20-25 05:15PM	New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Aug-18-25 08:05AM	Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 (Business Wire)
Aug-13-25 08:05AM	Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
Jul-18-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-27-25 08:05AM	Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) (Business Wire) -31.69%
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
May-23-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-22-25 09:05AM	Savara Announces Participation in Jefferies Global Healthcare Conference (Business Wire)
May-21-25 11:16AM	Savara Inc. (SVRA): Analysts See 212% Upside Potential (Insider Monkey) -7.18%
May-18-25 02:30PM	Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 (Business Wire)
May-13-25 04:05PM	Savara Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-12-25 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference (Business Wire) +5.59%
May-01-25 04:05PM	Savara Announces Participation in the Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-21-25 11:16AM	Savara: Make-It-Or-Break-It Molbreevi BLA Filing (Seeking Alpha)
Apr-11-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +10.61%
Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Sep-24-24 08:05AM	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Business Wire)
Sep-23-24 08:05AM	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Business Wire)
Sep-08-24 06:45AM	Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 (Business Wire)
Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.08%
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace) -8.19%
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26% -5.13%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace) -5.19%

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RAMSAY DAVID A	Director	Dec 19 '25	Sale	6.06	20,000	121,220	2,533,642	Dec 19 05:00 PM
RAMSAY DAVID A	Director	Dec 18 '25	Proposed Sale	6.11	20,000	122,200		Dec 18 11:17 AM
Elam Nevan C	Director	Dec 02 '25	Option Exercise	1.46	5,860	8,556	68,360	Dec 04 06:55 PM
Hawkins Richard J	Director	Nov 14 '25	Option Exercise	1.46	5,860	8,556	121,326	Nov 17 04:38 PM
Hawkins Richard J	Director	Jun 20 '25	Buy	2.04	48,225	98,572	115,466	Jun 23 02:39 PM
McCracken Joseph S	Director	May 29 '25	Buy	2.08	10,000	20,825	260,837	Jun 02 07:59 AM
RAMSAY DAVID A	Director	Mar 31 '25	Buy	2.77	150,000	416,250	2,513,642	Apr 01 07:00 AM

MBX

MBX Biosciences Inc

KRRO

Korro Bio Inc

NET

Cloudflare Inc

SVRA

Savara Inc

Upgrade your FINVIZ experience